44 related articles for article (PubMed ID: 1296148)
21. [Role of densitometry and scintigraphy in post-traumatic algodystrophy of the arms. Initial diagnosis and monitoring during treatment with carbocalcitonin].
Dore F; Melis GC; Fumu E; Casu AR; Piga M; Arru A; Vargiu P; Azzena MD; Madeddu G
Radiol Med; 1991; 81(1-2):114-7. PubMed ID: 2006318
[TBL] [Abstract][Full Text] [Related]
22. Ipriflavone and osteoporosis.
Schelonka EP; Usher A
JAMA; 2001 Oct; 286(15):1836-7. PubMed ID: 11597279
[No Abstract] [Full Text] [Related]
23. Effects of ipriflavone and estriol on postmenopausal osteoporotic changes.
Hanabayashi T; Imai A; Tamaya T
Int J Gynaecol Obstet; 1995 Oct; 51(1):63-4. PubMed ID: 8582523
[No Abstract] [Full Text] [Related]
24. Effect of avicatonin (chicken carbocalcitonin) on galvanic skin response: a randomized, prospective, double-blind, controlled study for an objective assessment of pain.
Fujita T; Fujii Y; Nakamura T; Miyauchi A; Takagi Y
Calcif Tissue Int; 2000 Apr; 66(4):243-7. PubMed ID: 10742438
[TBL] [Abstract][Full Text] [Related]
25. Effect and mechanisms of puerarin on the treatment of postmenopausal osteoporosis: A preliminary pre-clinical study.
Huang W; Guo Y; Han X; Xie X
Asian J Surg; 2023 Mar; 46(3):1332-1333. PubMed ID: 36117060
[No Abstract] [Full Text] [Related]
26. Ipriflavone: A New Non-Hormonal Therapeutic Agent in Osteoporosis. Satellite symposium proceedings. Florence, Italy, April 24, 1992.
Bone Miner; 1992 Oct; 19 Suppl 1():S1-64. PubMed ID: 1358372
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials.
Chen WC; Lin EY; Kang YN
Osteoporos Int; 2019 Sep; 30(9):1723-1732. PubMed ID: 31041475
[TBL] [Abstract][Full Text] [Related]
28. The future of ipriflavone in the management of osteoporotic syndromes.
Avioli LV
Calcif Tissue Int; 1997; 61 Suppl 1():S33-5. PubMed ID: 9263615
[No Abstract] [Full Text] [Related]
29. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
30. [Comparative analysis of therapeutic effects of carbocalcitonin and and conjugated estrogens in post-menopausal osteoporosis].
Surico N; Tavassoli K
Minerva Ginecol; 1990 Dec; 42(12):529-37. PubMed ID: 2089296
[TBL] [Abstract][Full Text] [Related]
31. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis.
Agnusdei D; Zacchei F; Bigazzi S; Cepollaro C; Nardi P; Montagnani M; Gennari C
Drugs Exp Clin Res; 1989; 15(2):97-104. PubMed ID: 2661184
[TBL] [Abstract][Full Text] [Related]
32. [Experience with ipriflavone therapy in postmenopausal osteoporosis].
Szántó F
Orv Hetil; 1997 Nov; 138(44):2801-3. PubMed ID: 9411349
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of ovariectomized patients with intramuscular and nasal-spray synthetic calcitonin].
Zara C; Perotti F; Ferraro R; Lauri A; Saviotti C; Montrasio MG; Caprotti M; Polatti F
Minerva Endocrinol; 1989; 14(1):53-6. PubMed ID: 2733647
[TBL] [Abstract][Full Text] [Related]
34. [Randomized comparative study using carbocalcitonin i.m. vs carbocalcitonin nasal spray vs ipriflavone x os in the treatment of post-menopausal osteoporosis].
Lobianco R; Merola B; Lupoli G; Cocca A; Guarino M; Pia M; Guerriero S; Lombardi G
Minerva Endocrinol; 1992; 17(2):79-84. PubMed ID: 1296148
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
